Most patients (87.3%) in the MPN group received standard therapies including at least one medication, such as aspirin, anticoagulants, hydroxyurea, JAK2 inhibitors, or IFN-α (Supplemental Table 1). This evidence concerns the gene JAK2 and myeloproliferative neoplasm.